8-K/A: Windtree Therapeutics Inks Deal to Source Manufacturing for Evofem's FDA-Approved Contraceptive, PHEXXI

Windtree Therapeutics announces a License and Supply Agreement with Evofem Biosciences to become the sourcing partner for PHEXXI, aiming to reduce manufacturing costs and expand global availability.

Summary

• Windtree Therapeutics has entered into a License and Supply Agreement with Evofem Biosciences to become the sourcing partner for PHEXXI, an FDA-approved hormone-free contraceptive vaginal gel.
• The goal is to reduce manufacturing costs for PHEXXI, potentially enabling Evofem to expand its availability in price-sensitive global markets.
• PHEXXI's annual revenues have exceeded $19 million, with over 96,000 boxes sold in 2024.
• Windtree's new corporate strategy, announced in January 2025, focuses on becoming a revenue-generating biotech.
• Windtree anticipates its manufacturing partner will assist with tech transfer and manufacture initial and validation batches in line with FDA requirements.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive. The agreement represents a concrete step towards Windtree's goal of becoming a revenue-generating biotech. However, the success of the partnership is contingent on several factors, including securing a manufacturing partner and regulatory approvals.

Positives

• Windtree's new strategy to become a revenue-generating biotech is underway.
• The partnership with Evofem could lead to profitable revenue generation for Windtree.
• Reducing manufacturing costs for PHEXXI could expand its global market reach.
• PHEXXI is an FDA-approved product with existing revenue, reducing market risk.
• Windtree has extensive contacts across the globe to assist with manufacturing.

Negatives

• The success of the agreement depends on Windtree's ability to secure a manufacturing partner that can significantly reduce costs.
• The agreement is subject to regulatory requirements and technology transfer risks.
• Windtree's ability to generate revenue from this agreement is dependent on Evofem's continued commercialization of PHEXXI.

Risks

• Windtree's ability to acquire revenue-generating subsidiaries is uncertain.
• Securing additional capital when needed is a risk.
• The success and advancement of clinical development programs for istaroxime and other product candidates are subject to risks and uncertainties.
• Delays in manufacturing drug products, drug substances, and other materials could occur.
• Regulatory authorities may not agree with the company on matters raised during regulatory reviews.
• The company may never realize the value of its intangible assets and have to incur future impairment charges.
• The economic and social consequences of the COVID-19 pandemic and the impacts of political unrest could have an adverse impact on the company's operations.

Future Outlook

Windtree anticipates that its manufacturing partner will work with them on tech transfer and manufacturing initial and validation batches in line with FDA requirements, with the goal of Evofem expanding PHEXXI into new global markets.

Management Comments

• Jed Latkin, CEO of Windtree, stated that the License and Supply Agreement with Evofem is a first step in their plan to generate profitable revenue to provide value to stockholders.
• Saundra Pelletier, CEO of Evofem, believes that the decrease in the per-box cost of PHEXXI will allow Evofem to take PHEXXI into new, price-sensitive global markets.

Industry Context

This announcement reflects a trend in the pharmaceutical industry where companies are seeking strategic partnerships to optimize manufacturing costs and expand market reach for existing products. It also highlights the growing demand for non-hormonal contraceptive options.

Comparison to Industry Standards

• Contract manufacturing is a common practice in the pharmaceutical industry, with companies like Catalent and Lonza providing services to optimize production costs.
• The $19 million in annual revenue for PHEXXI is relatively modest compared to blockbuster contraceptive drugs, but it represents a significant opportunity for growth if manufacturing costs can be reduced.
• Evofem's strategy to partner for global expansion aligns with industry trends, as many pharmaceutical companies rely on collaborations to enter new markets.

Stakeholder Impact

• Shareholders may benefit from potential revenue generation and increased value.
• Employees may see new opportunities related to the manufacturing partnership.
• Customers (women) may benefit from increased availability of PHEXXI in global markets.
• Evofem may benefit from reduced manufacturing costs and expanded market reach.

Next Steps

• Windtree will work with its manufacturing partner on tech transfer and manufacturing initial and validation batches.
• Evofem will continue to commercialize PHEXXI in the United States and internationally through strategic partnerships.
• Evofem plans to expand PHEXXI's availability in new, price-sensitive global markets.

Key Dates

Keywords

Windtree Therapeutics, Evofem Biosciences, PHEXXI, License Agreement, Supply Agreement, Manufacturing, Contraceptive, Revenue Generation, Biotech